ADAM17 and cardiac hypertrophy: There is evidence showing that vascular ADAM17-deficient mice and ADAM17 antibody treated mice have alleviated Ang II-induced cardiac hypertrophy, vascular medial hypertrophy, and perivascular fibrosis via activating EGFR, which is independent of blood pressure regulation [14, 25].